Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Strong Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Tonix Pharmaceuticals Holding Corp. (TNXP)

Pharmaceutical Preparations

https://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.

26 MAIN STREET, SUITE 101
CHATHAM, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/13/2009

Market Cap

10,368,440

Shares Outstanding

80,820,000

Weighted SO

58,614,593

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

SONN --.--%

ONTX --.--%

PALI --.--%

IBIO --.--%

JAGX --.--%

ACST --.--%

DFFN --.--%

VXRT --.--%

VBIV --.--%

Beta

2.1340

Last Div

0.0000

Range

0.4021-32.32

Chg

0.0331

Avg Vol

2097398

Mkt Cap

10368440

Exch

NASDAQ

Country

US

Phone

862 799 8599

DCF Diff

-1.5824

DCF

2.7607

Div Yield

0.0000

P/S

1.0116

EV Multiple

-0.1270

P/FV

0.3664

Div Yield %

0.0000

P/E

-0.4019

PEG

-0.0061

Payout

0.0000

Current Ratio

1.4697

Quick Ratio

0.8666

Cash Ratio

0.3442

DSO

0.0000

DIO

122.1910

Op Cycle

122.1910

DPO

65.7799

CCC

56.4111

Gross Margin

-2.5994

Op Margin

-10.3248

Pretax Margin

-9.6187

Net Margin

-9.6187

Eff Tax Rate

-0.2696

ROA

-0.7285

ROE

-0.8303

ROCE

-0.9213

NI/EBT

1.0000

EBT/EBIT

0.9316

EBIT/Rev

-10.3248

Debt Ratio

0.0684

D/E

0.0856

LT Debt/Cap

0.0539

Total Debt/Cap

0.0788

Int Coverage

-59.1223

CF/Debt

-9.2939

Equity Multi

1.2515

Rec Turnover

999999.9999

Pay Turnover

5.5488

Inv Turnover

2.9871

FA Turnover

0.1093

Asset Turnover

0.0757

OCF/Share

-1.0635

FCF/Share

-1.1145

Cash/Share

0.0872

OCF/Sales

-8.3917

FCF/OCF

1.0479

CF Coverage

-9.2939

ST Coverage

-27.7736

CapEx Coverage

-20.8690

Div&CapEx Cov

-20.8690

P/BV

0.3664

P/B

0.3664

P/S

1.0116

P/E

-0.4019

P/FCF

-0.1150

P/OCF

-0.4606

P/CF

-0.4606

PEG

-0.0061

P/S

1.0116

EV Multiple

-0.1270

P/FV

0.3664

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 20, 10:35 Tonix Pharmaceuticals Announces Registered Direct Offering of up to $144 Million GlobeNewswire Inc. Dec 20, 10:35 Tonix Pharmaceuticals Announces Registered Direct Offering of up to $144 Million GlobeNewswire Inc. Dec 20, 10:30 Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia MarketWatch Oct 31, 19:16 Tonix shares sink 29% on discontinued development on depression treatment MarketWatch Oct 31, 19:16 Tonix shares sink 29% on discontinued development on depression treatment GlobeNewswire Inc. Oct 30, 07:00 Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress

Revenue Product Segmentation